Table 1 Baseline characteristics of patients analyzed with tissue samples.

From: Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors

Characteristics

Success (N = 65)

Failure (N = 17)

P value

Age (years)

  >65

32 (49.2%)

10 (58.8%)

1.00

  ≤65

33 (50.8%)

7 (41.2%)

 

Sex

  Male

37 (56.9%)

9 (52.9%)

1.00

  Female

28 (43.1%)

8 (47.1%)

 

Primary site of tumor

  Stomach

26 (40.0%)

9 (52.9%)

0.112

  Small intestine

31 (47.4%)

5 (29.4%)

 

  Rectum

3 (4.6%)

3(17.6%)

 

  Others

5 (7.7%)

0

 

Specimen collection methods

  Biopsy

9 (13.8%)

5 (29.4%)

0.234

  Surgical resection

53 (81.5%)

12 (70.6%)

 

  Others

3 (4.6%)

0

 

Specimen collection sites

  Primary lesion

46 (70.8%)

7 (41.2%)

0.047

  Metastatic lesion

19 (29.2%)

10 (58.8%)

 

    Liver

11

6

 

    Peritoneum

6

3

 

    Lung

1

0

 

    Bone

0

1

 

    Skin

1

0

 

Prior targeted therapy

  Performed

12 (18.5%)

8 (47.1%)

0.033

  Not performed

53 (81.5%)

9 (52.9%)